Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Mitsubishi Chemical Licenses SPR Technology from Quantech
February 19, 2001
- REGULATORY NEWS IN BRIEF -2-
February 12, 2001
- Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
- Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
- Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
- Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
- Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
- Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
- Serious ADR Reported for Sarpogrelate
February 12, 2001
- Daiichi Starts Drug Discovery Research in New Laboratory
February 12, 2001
- Kirin Brewery Wins Epoetin Patent Suit Against Snow Brand Milk
February 12, 2001
- Typographical Error Found in NHI Price of Lorcam Presented to Chuikyo
February 12, 2001
- Non-compliance with GCP Found in 1,529 Cases in 3-year Survey
February 12, 2001
- Fukujin Ties Up with Inagaki Yakuhin
February 12, 2001
- OTC NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -1-
February 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -2-
February 12, 2001
- DIAGNOSIS NEWS IN BRIEF
February 12, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…